Drug reference

Necitumumab

Monoclonal Antibody · Antineoplastic

Monoclonal AntibodyAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

1 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactions

ThalidomideSevereDatabaseDDInter

Mechanism

Necitumumab is an IgG1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR). It inhibits downstream EGFR signaling and enhances the response to chemotherapy and radiotherapy.

Indications

Locally advanced or metastatic epidermal growth factor receptor expressing squamous non-small-cell lung cancer, in patients who have not received previous chemotherapy (in combination with gemcitabine and cisplatin) (specialist use only)first-line treatment of patients with metastatic, squamous NSCLC in combination with gemcitabine and cisplatin

Dosing

Adult: BY INTRAVENOUS INFUSION: 800 mg once daily on days 1 and 8 of a 3-week cycle, for up to 6 cycles. Patients whose disease has not progressed after combination therapy may continue with necitumumab monotherapy.
Max dose: 800 mg per dose on administration days

Contraindications

Cardiorespiratory disorders (no information available)
History of thromboembolic events
Patients with multiple risk factors for thromboembolic events (unless benefits outweigh risks)

Side effects

Common

ConjunctivitisDysuriaElectrolyte imbalanceEmbolism and thrombosisFeverHaemorrhageHeadacheSkin rashHypomagnesemiaFatigueInfusion reactionsimilar to cetuximab

Serious

Tumour lysis syndrome
Thromboembolic events (venous and arterial)
Interstitial lung disease

Pregnancy & lactation

Lactation

Manufacturer advises avoid during first few days after birth due to possible risk from transfer of antibodies to infant. After this time, use during breastfeeding only if clinically needed.